Results for levonorgestrel translation from Slovenian to English

levonorgestrel.
levonorgestrel.

levonorgestrel 150
levonorgestrel 150 mcg qd

levonorgestrel (aktivni
cmin: 0 82% (0 79 to 0 85)

etinilestradiol in levonorgestrel
ethinyl estradiol and levonorgestrel

etinilestradiol (ee)/levonorgestrel (lng)
ethinyl oestradiol (ee) / levonorgestrel (lng)

intrauterini sistem, ki sprošča levonorgestrel,
levonorgestrel-releasing intrauterine system

intrauterini sistem (ius), ki sprošča levonorgestrel
levonorgestrel-releasing intrauterine system (ius)

mednarodno nelastniško ime (inn): levonorgestrel in etinilestradiol
opinion following an article 29(2) referral rigevidon international non-proprietary name (inn): levonorgestrel and ethinylestradiol

vsadek; intrauterini sistem (ius), ki sprošča levonorgestrel;
levonorgestrel-releasing intrauterine system (ius)

v tej študiji je bilo zdravilo ellaone pri preprečevanju nosečnosti enako učinkovito kot levonorgestrel.
in this study, ellaone was as effective as levonorgestrel at preventing pregnancies.

zdravilo fycompa lahko povzroči manjšo učinkovitost nekaterih hormonskih kontraceptivov, kot je levonorgestrel.
fycompa may make certain hormonal contraceptives such as levonorgestrel less effective.

zdravila ellaone ne uporabljajte skupaj z drugimi nujnimi kontracepcijskimi tabletami, ki vsebujejo levonorgestrel.
do not use ellaone together with another emergency contraceptive pill that contains levonorgestrel.

zdravila, ki vsebujejo levonorgestrel, norgestimat ali noretisteron, so povezana z najmanjšim tveganjem za vte.
products that contain levonorgestrel, norgestimate or norethisterone are associated with the lowest risk of vte.

v prisotnosti fesoterodina ni sprememb plazemskih koncentracij kombiniranih peroralnih kontraceptivov, ki vsebujejo etinilestradiol in levonorgestrel.
in the presence of fesoterodine there are no changes in the plasma concentrations of combined oral contraceptives containing ethinylestradiol and levonorgestrel.

Čeprav mirena sprošča levonorgestrel v zelo majhnih odmerkih, se za podatke zdi, da so ustrezni tudi za implantante.
although mirena releases levonorgestrel in a very low dose, the data would seem to be relevant also for implants.

ta študija primerja tveganje uporabe nomegestrola/estradiola s tveganjem uporabe kombiniranih peroralnih kontraceptivov, ki vsebujejo levonorgestrel.
this study compares the risk of nomegestrol/estradiol use with the risk of levonorgestrel-containing combined oral contraceptive use.

vsadki in intrauterini sistemi, ki sproščajo levonorgestrel, so povezani s povečanim tveganjem za okužbe v času vstavitve in neredne vaginalne krvavitve.
implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding.

ocenjuje se, da se bo vte v enem letu razvila pri približno 61 od 10.000 žensk, ki uporabljajo nizkoodmerne chc, ki vsebujejo levonorgestrel.
it is estimated that out of 10,000 women who use a low dose chc that contains levonorgestrel, about 61 will develop a vte in one year.

ni še znano, kakšno je tveganje za nastanek krvnega strdka med uporabo zdravila ioa v primerjavi s tveganjem med uporabo kombiniranega hormonskega kontraceptiva, ki vsebuje levonorgestrel.
it is not yet known how the risk of a blood clot with ioa compares to the risk with a combined hormonal contraceptive that contains levonorgestrel.

med 10.000 ženskami, ki uporabljajo kombiniran hormonski kontraceptiv, ki vsebuje levonorgestrel, noretisteron ali norgestimat, se v enem letu krvni strdek pojavi pri približno 5 do 7 ženskah.
out of 10,000 women who are using a combined hormonal contraceptive that contains levonorgestrel, norethisterone, or norgestimate, about 5-7 will develop a blood clot in a year.